Overview and Scope
Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition that predominantly impacts the axial skeleton, encompassing the spine and sacroiliac joints. It is characterized by inflammation in the sacroiliac joints, resulting in persistent back pain and stiffness.
Sizing and Forecast
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support:. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Segmentation & Regional Insights
The axial spondyloarthritis (axspa) market covered in this report is segmented –
1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient’s quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis’s Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
Key Industry Players
Major companies operating in the axial spondyloarthritis (axspa) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc.
The axial spondyloarthritis (axspa) market report table of contents includes:
1. Executive Summary
2. Axial Spondyloarthritis (axSpA) Market Characteristics
3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies
4. Axial Spondyloarthritis (axSpA) Market – Macro Economic Scenario
5. Global Axial Spondyloarthritis (axSpA) Market Size and Growth
.
.
.
32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking
33. Global Axial Spondyloarthritis (axSpA) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market
35. Axial Spondyloarthritis (axSpA) Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
